The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Acute Promyelocytic Leukemia: PML-RARA Driven Disease Management

Highly curable AML subtype with targeted therapy combining ATRA and arsenic trioxide

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Acute Promyelocytic Leukemia: PML-RARA Driven Disease Management?

APL accounts for approximately 10 percent of acute myeloid leukemia cases with characteristic t(15;17) translocation creating PML-RARA fusion oncogene.

Morphologic features include hypergranular or microgranular promyelocytes with characteristic Auer rods and faggot cells.

Genetic confirmation requires PML-RARA fusion detection by FISH, RT-PCR or cytogenetics with rapid turnaround essential for treatment decisions.

Disseminated intravascular coagulation and hyperfibrinolysis are characteristic life-threatening complications requiring immediate management.

Risk stratification at diagnosis using Sanz score based on white blood cell count and platelet count guides treatment intensity.

Symptoms

Bleeding manifestations from coagulopathy with bruising, petechiae, mucosal bleeding and severe hemorrhage including intracranial bleeding.
Fatigue, weakness and pallor from anemia with associated cytopenias.
Fever may be present though leukocyte count is typically normal or low at presentation.
Catastrophic bleeding events particularly intracranial hemorrhage represent the leading cause of early death.
Differentiation syndrome during treatment with ATRA characterized by fever, dyspnea, weight gain and pulmonary infiltrates.

Risk Factors

No clearly established environmental risk factors for sporadic disease.
Prior cytotoxic therapy with topoisomerase II inhibitors (anthracyclines, mitoxantrone) for previous malignancy.
Variable presentation across age groups with younger patients more common compared with other AML subtypes.
Hispanic ethnicity reported with higher prevalence in some populations.
Body mass index and obesity may influence relapse risk in some studies.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Acute leukemia presentation with bleeding symptoms and characteristic morphology requires immediate hematology consultation.
  • Suspected APL warrants immediate ATRA initiation while awaiting genetic confirmation due to bleeding risk.
  • Differentiation syndrome symptoms during induction therapy require urgent recognition and corticosteroid treatment.
  • Persistent or recurrent symptoms during treatment need prompt reassessment for treatment response or complications.
  • Long-term follow-up with regular minimal residual disease monitoring is essential despite excellent prognosis.

Treatment Methods

01
Immediate ATRA initiation upon clinical suspicion before genetic confirmation due to severe bleeding risk in untreated APL.
02
Standard induction with ATRA plus arsenic trioxide for low/intermediate risk patients eliminating need for cytotoxic chemotherapy.
03
ATRA, arsenic and chemotherapy (idarubicin) combination for high-risk disease with white blood cell count above 10×10⁹/L.
04
Aggressive supportive care for coagulopathy with platelet, fresh frozen plasma and cryoprecipitate transfusions to maintain target levels.
05
Comprehensive multidisciplinary care including monitoring for differentiation syndrome with corticosteroid prophylaxis or treatment, central nervous system prophylaxis in selected cases, minimal residual disease monitoring with PML-RARA quantification, and excellent long-term outcomes with cure rates exceeding 90 percent in modern era.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.